A more recent pooled post hoc long-term analysis of interventional trials and their open-label extension studies concluded that time on Ocrelizumab and abnormal IgG levels were not significantly associated with an increased severe infection risk, but, rather, abnormal IgM levels. Here, CD40LG is linked to infection.